Independent clinical laboratory industry has experienced less than 20 years’ development in China, but there were more than 110 independent clinical laboratories in China with rapid development. Kingmed, Adicon and Dian placed on the top three respectively among large-scale chain-store clinical laboratories. Market scale was approximately CNY 2.5 billion in 2012, only accounting for about 1.5% of market shares in clinical laboratory industry currently. But in America, independent clinical laboratory industry accounted for one third of market shares, so there is still a big gap when compared with America. Radiant Insights takes a view that sales value of Kingmed firstly broke through CNY 1 billion as of 2012, which can be deemed as China independent clinical laboratory industry entered rapid-growth period.
Download Full Research Report of China Independent Clinical Laboratory Market @ http://www.radiantinsights.com/research/research-and-development-trend-of-china-independent-clinical-laboratory-market-2013-2017
Under the background of new medical reform, independent clinical laboratory industry will further expand so as to enter rapid-growth period. During this period, increasing new entrants will step into this industry, chain enterprises and solo independent laboratory will coexist. But in the long run, chain enterprises are equipped with the capacities of large-scale purchase and standard management and administration for reducing production costs; service network layout will obtain brand effect for attracting customers. However, the service of solo independent laboratory is limited within 400 kilometers, customer resources are inclined to be saturated. In addition, it will drop out the market along with losses because of declined prices. Thus chain enterprises are expected to be still prosperous.
Request a Free Sample Copy of this Report @ http://www.radiantinsights.com/research/research-and-development-trend-of-china-independent-clinical-laboratory-market-2013-2017/request-sample
Through comparing testing project reserves, layout of service network station and management and administration capability in domestic chain enterprises, Radiant Insights holds a view of Kingmed owns absolute competitive advantages and will keep its leading position in industry due to high-end project reserves and many laboratories are widely distributed; Adicon and Dian placed on the second, Adicon has high-end project reserves and strict quality control standards, while Dian owns differentiation competitive advantages such as level-to-level administration laboratories, increase output and ” agency + service ” mode for reducing purchasing costs etc.; DAAN Gene started late (2007), so it is slightly inferior to the other three enterprises.
“Research and Development Trend of China Independent Clinical Laboratory Market, 2013-2017” mainly conducts an in-depth market research on development environment and market status quo of China independent clinical laboratory industry, makes an analysis of domestic market status quo, supply and demand, upstream and downstream industries and business performance of key enterprises, meanwhile makes a forecast for the industry so as to provide a decision-making reference for enterprises to understand and invest such industry.
Read more related reports by Radiant Insights:
• Coronary Stent Industry
The demand for interventional medical core products has increased continuously with the improvement of living quality and the coming of aging society; PCI (percutaneous coronary intervention) surgical cases also increased year by year. In 2012, the usage quantity of coronary stent was about 633,600 sets and the market scale reached CNY 3.15 billion in China. The overall market share of domestic brands decreased to 65% in 2012 from 70% in 2011. However, the landscape of Top 3 enterprises was not changed; MicroPort still occupied the leading position with 23% market shares, following by LePu and Shandong JW with 21% and 20% market shares respectively.
• Blood Products Industry
The per capita blood products consumption of Chinese residents is extremely low, and there is a relatively large gap compares with the developed countries. China’s albumin supply has been tight, and the annual growth rate will be about 15% in the future. The per capita consumption of human immunoglobulin for intravenous injection is only 10% of the foreign countries, since 2004, the growth rate in this aspect has been maintaining at the level of more than 30%; at present, this application in small and medium-scale hospitals is still unpopular, and the development potential is relatively huge; as for the sales of coagulation factor products, China is still in its infancy, compares with foreign market share of 40%, China owns a broad market space.
About Radiant Insights, Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Corporate Sales Specialist, USA
Radiant Insights, Inc
Toll Free: 1-888-202-9519